Glatiramer Acetate Injection, Solution
Product Images NDC 0378-6960

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 0378-6960). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Time To Second Exacerbation (327c5127 6727 4cf8 Acea 838e5f9af458 01)

This appears to be a table or chart with data related to medical research, specifically related to the use of glatiramer acetate in treating multiple sclerosis. The percentages appear to be related to the likelihood or frequency of a second exacerbation occurring, with a hazard ratio of 0%. The value of p is also given as 0.0005. The significance or implications of this data are not provided by the text.*

FDA Label Image

Figure 2: Median Cumulative Number Of Gd-enhancing Lesions (327c5127 6727 4cf8 Acea 838e5f9af458 02)

This appears to be a comparison chart between Glatiramer Acetate and a placebo, with the values of 18 and 16 appearing under each option, likely representing some sort of measurement or evaluation. The chart also includes some symbols that may be related to statistical analysis. Without further context, the purpose or significance of this chart is not clear.*

FDA Label Image

Glatiramer Acetate Injection 20 mg/ml Carton Label (Image 01)

This appears to be a product label or description for a medication containing Glatiramer Acetate. It includes instructions for use via subcutaneous injection, details regarding storage requirements, dosage information, and information about the manufacturer and distribution.*

FDA Label Image

Instructions For Use Figure A (Image 02)

The text appears to be a list of items, including "Starps", "Blsposal", "Contaner", "Coton Bals", "Syrnge n Blster Package", and "RicanolWipss". The last item is unclear, and there is a reference to "Figure A" which cannot be evaluated without context. It is not clear what the purpose or context of this list is, so a useful description cannot be provided.*

FDA Label Image

Instructions For Use Figure B (Image 03)

FDA Label Image

Instructions For Use Figure C (Image 04)

This is a set of instructions for body waxing, specifying areas to avoid on the abdomen, back of hips, and arms, as well as the thighs. It notes areas around the belly button and upper hips should be avoided, as well as areas of fleshy skin on the back of the arms and the upper thighs. It provides a visual guide with a labeled Figure C.*

FDA Label Image

Instructions For Use Figure D (Image 05)

FDA Label Image

Instructions For Use Figure E (Image 06)

FDA Label Image

Instructions For Use Figure F (Image 07)

FDA Label Image

Instructions For Use Figure G (Image 08)

FDA Label Image

Instructions For Use Figure H (Image 09)

FDA Label Image

Instructions For Use Figure I (Image 10)

FDA Label Image

Instructions For Use Figure J (Image 11)

FDA Label Image

Instructions For Use Figure K (Image 12)

FDA Label Image

Instructions For Use Figure L (Image 13)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.